275 related articles for article (PubMed ID: 1503978)
1. Tetrazolium [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] reduction by mycoplasmas.
Kirchhoff H; Maass C; Runge M; Franz B; Schmidt R; Quentmeier H; Mühlradt PF
Int J Syst Bacteriol; 1992 Jul; 42(3):506-8. PubMed ID: 1503978
[TBL] [Abstract][Full Text] [Related]
2. Effects of the pH dependence of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-tetrazolium bromide-formazan absorption on chemosensitivity determined by a novel tetrazolium-based assay.
Plumb JA; Milroy R; Kaye SB
Cancer Res; 1989 Aug; 49(16):4435-40. PubMed ID: 2743332
[TBL] [Abstract][Full Text] [Related]
3. Falsification of tetrazolium dye (MTT) based cytotoxicity assay results due to mycoplasma contamination of cell cultures.
Denecke J; Becker K; Jürgens H; Gross R; Wolff JE
Anticancer Res; 1999; 19(2A):1245-8. PubMed ID: 10368683
[TBL] [Abstract][Full Text] [Related]
4. Characterization of the cellular reduction of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT): subcellular localization, substrate dependence, and involvement of mitochondrial electron transport in MTT reduction.
Berridge MV; Tan AS
Arch Biochem Biophys; 1993 Jun; 303(2):474-82. PubMed ID: 8390225
[TBL] [Abstract][Full Text] [Related]
5. An improved 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) reduction assay for evaluating the viability of Escherichia coli cells.
Wang H; Cheng H; Wang F; Wei D; Wang X
J Microbiol Methods; 2010 Sep; 82(3):330-3. PubMed ID: 20619304
[TBL] [Abstract][Full Text] [Related]
6. Current methodology of MTT assay in bacteria - A review.
Grela E; Kozłowska J; Grabowiecka A
Acta Histochem; 2018 May; 120(4):303-311. PubMed ID: 29606555
[TBL] [Abstract][Full Text] [Related]
7. Cytotoxic amyloid peptides inhibit cellular 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) reduction by enhancing MTT formazan exocytosis.
Liu Y; Schubert D
J Neurochem; 1997 Dec; 69(6):2285-93. PubMed ID: 9375659
[TBL] [Abstract][Full Text] [Related]
8. The noncellular reduction of MTT tetrazolium salt by TiO₂ nanoparticles and its implications for cytotoxicity assays.
Lupu AR; Popescu T
Toxicol In Vitro; 2013 Aug; 27(5):1445-50. PubMed ID: 23531555
[TBL] [Abstract][Full Text] [Related]
9. Mechanism of cellular 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) reduction.
Liu Y; Peterson DA; Kimura H; Schubert D
J Neurochem; 1997 Aug; 69(2):581-93. PubMed ID: 9231715
[TBL] [Abstract][Full Text] [Related]
10. The role of plasma membrane in bioreduction of two tetrazolium salts, MTT, and CTC.
Bernas T; Dobrucki JW
Arch Biochem Biophys; 2000 Aug; 380(1):108-16. PubMed ID: 10900139
[TBL] [Abstract][Full Text] [Related]
11. A rapid colorimetric assay of killer toxin activity in yeast.
Hodgson VJ; Walker GM; Button D
FEMS Microbiol Lett; 1994 Jul; 120(1-2):201-5. PubMed ID: 8056291
[TBL] [Abstract][Full Text] [Related]
12. Toxicity of protein aggregates in PC12 cells: 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay.
Shearman MS
Methods Enzymol; 1999; 309():716-23. PubMed ID: 10507057
[No Abstract] [Full Text] [Related]
13. Limitations of the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-2H-tetrazolium bromide (MTT) assay when compared to three commonly used cell enumeration assays.
van Tonder A; Joubert AM; Cromarty AD
BMC Res Notes; 2015 Feb; 8():47. PubMed ID: 25884200
[TBL] [Abstract][Full Text] [Related]
14. Cell sensitivity assays: the MTT assay.
van Meerloo J; Kaspers GJ; Cloos J
Methods Mol Biol; 2011; 731():237-45. PubMed ID: 21516412
[TBL] [Abstract][Full Text] [Related]
15. Cell-based quantitative evaluation of the MTT assay.
Molinari BL; Tasat DR; Palmieri MA; O'Connor SE; Cabrini RL
Anal Quant Cytol Histol; 2003 Oct; 25(5):254-62. PubMed ID: 14603722
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of MTT assay for measurement of emodin-induced cytotoxicity.
Wang X; Ge J; Wang K; Qian J; Zou Y
Assay Drug Dev Technol; 2006 Apr; 4(2):203-7. PubMed ID: 16712424
[TBL] [Abstract][Full Text] [Related]
17. Enhancement of MTT, a tetrazolium salt, exocytosis by amyloid beta-protein and chloroquine in cultured rat astrocytes.
Isobe I; Michikawa M; Yanagisawa K
Neurosci Lett; 1999 May; 266(2):129-32. PubMed ID: 10353344
[TBL] [Abstract][Full Text] [Related]
18. Application of the MTT assay to human prostate cancer cell lines in vitro: establishment of test conditions and assessment of hormone-stimulated growth and drug-induced cytostatic and cytotoxic effects.
Romijn JC; Verkoelen CF; Schroeder FH
Prostate; 1988; 12(1):99-110. PubMed ID: 3126493
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of a soluble tetrazolium/formazan assay for cell growth and drug sensitivity in culture using human and other tumor cell lines.
Scudiero DA; Shoemaker RH; Paull KD; Monks A; Tierney S; Nofziger TH; Currens MJ; Seniff D; Boyd MR
Cancer Res; 1988 Sep; 48(17):4827-33. PubMed ID: 3409223
[TBL] [Abstract][Full Text] [Related]
20. Inhibitors of V-type ATPases, bafilomycin A1 and concanamycin A, protect against beta-amyloid-mediated effects on 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) reduction.
Kane MD; Schwarz RD; St Pierre L; Watson MD; Emmerling MR; Boxer PA; Walker GK
J Neurochem; 1999 May; 72(5):1939-47. PubMed ID: 10217271
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
